• 1. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids and derivatives Piperidinecarboxylic acids

Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate (CAS No. 1258638-04-8): A Comprehensive Overview

Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate, identified by its CAS number 1258638-04-8, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the piperidine class of heterocyclic amines, characterized by a six-membered ring containing one nitrogen atom. The presence of a tert-butyl group at the 1-position and a 1-cyano-1-methylethyl group at the 4-position introduces unique electronic and steric properties, making it a valuable intermediate in the synthesis of biologically active molecules.

The< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate molecule exhibits a high degree of structural complexity, which contributes to its versatility in drug design. The tert-butyl group, a bulky alkyl substituent, enhances the compound's lipophilicity, facilitating its interaction with lipid bilayers in biological membranes. This property is particularly useful in the development of orally active drugs that require efficient absorption through the gastrointestinal tract. Additionally, the cyano group introduces a polar functional moiety, improving solubility in aqueous environments and enabling better penetration into cellular compartments.

Recent advancements in computational chemistry have highlighted the< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate as a promising scaffold for designing novel therapeutic agents. Molecular modeling studies have demonstrated that this compound can effectively modulate enzyme activity by occupying specific binding pockets within target proteins. For instance, its structural features are well-suited for inhibiting kinases and phosphodiesterases, which are critical enzymes involved in various signaling pathways associated with diseases such as cancer and neurodegeneration.

In the realm of drug discovery, the< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate has been employed in the development of small-molecule inhibitors targeting protein-protein interactions. These interactions are often pivotal in maintaining cellular homeostasis and are dysregulated in numerous pathological conditions. By designing molecules that selectively disrupt these interactions, researchers aim to develop treatments for conditions like inflammation, autoimmune disorders, and infectious diseases. The compound's ability to engage with multiple binding sites on target proteins underscores its potential as a versatile pharmacophore.

The synthesis of< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Key synthetic strategies include nucleophilic substitution reactions, cyclization processes, and protecting group chemistry. The introduction of the tert-butyl group typically involves alkylation reactions using appropriate reagents such as tert-butanol or diethyl carbonate under acidic or basic catalysis. Subsequent functionalization with the 1-cyano-1-methylethyl group requires careful selection of cyanating agents and reaction conditions to avoid side products.

Recent studies have explored the< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate as a building block for peptidomimetics—molecules designed to mimic the structure and function of natural peptides but with improved stability and bioavailability. Peptidomimetics have gained prominence in drug development due to their ability to interact with peptide receptors without triggering immune responses associated with actual peptides. The piperidine core provides a rigid framework that maintains the conformational integrity of peptidomimetic analogs, enhancing their binding affinity and therapeutic efficacy.

The pharmacokinetic properties of< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate have been extensively studied to optimize its delivery systems. Researchers have investigated various formulations, including prodrugs and nanoparticles, to enhance bioavailability and target specificity. Prodrug strategies involve converting the compound into a less active form that is later metabolized into its active form within the body. Nanoparticle delivery systems offer controlled release profiles and improved cellular uptake, making them particularly useful for treating diseases that require localized drug action.

The< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate has also shown promise in preclinical models as an anti-inflammatory agent. In vitro studies have demonstrated its ability to inhibit inflammatory cytokine production by modulating signaling pathways such as NF-κB and MAPK. These pathways are central to inflammatory responses and are implicated in chronic diseases like rheumatoid arthritis and inflammatory bowel disease. Animal models have further supported these findings by showing reduced inflammation and tissue damage following treatment with derivatives of this compound.

The development of next-generation sequencing technologies has enabled high-throughput screening (HTS) approaches for identifying novel drug candidates like< strong>Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate. HTS allows researchers to rapidly test thousands of compounds against biological targets, accelerating the drug discovery process. Computational methods such as virtual screening have been employed to predict potential hits before experimental validation, reducing costs and time associated with traditional screening methods. These advancements have significantly enhanced the efficiency of identifying promising candidates for further development.

The future directions for research on< strong>Tert-butyl 4-(1-cyano-1-methylethylethypiperidine carbox ylate include exploring its role in central nervous system (CNS) disorders such as Alzheimer's disease and Parkinson's disease. Preclinical evidence suggests that piperidine-based compounds can cross the blood-brain barrier due to their favorable pharmacokinetic properties. By leveraging this advantage, researchers aim to develop treatments that address neurological deficits caused by these diseases without significant side effects.

In conclusion,< strong>Tert-butyl 4-(l-cyano-l -methyleth ylpiperid ine-l -carb oxyla te, CAS No.< strong>1258638--04--8, represents a significant advancement in pharmaceutical chemistry with its unique structural features and versatile applications. Its role as an intermediate in drug synthesis, modulator of biological pathways, and potential therapeutic agent underscores its importance in modern medicine. Continued research efforts will likely uncover new applications for this compound, further solidifying its position as a cornerstone in medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)